GlassScriptPhysician profile
Austin O Williams
NPI 1255433611
$4,727.78
in general payments reported to CMS, 2019-2025
40 companies · $1,329 in 2025
The $1,329 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $347 · 2020: $243 · 2021: $530 · 2022: $938 · 2023: $776 · 2024: $564 · 2025: $1,329.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,669.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,669.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $776.20 | 2021-2025 | |
| Amgen INC. | $480.60 | 2019-2025 | Krystexxa, Repatha, Repatha |
| Otsuka America Pharmaceutical, INC. | $395.00 | 2019-2025 | Jynarque, Voyxact |
| Mallinckrodt Hospital Products INC. | $304.65 | 2020-2025 | Acthar |
| Abbvie INC. | $274.36 | 2022-2025 | Dalvance, Teflaro, Avycaz |
| Lilly USA, LLC | $226.98 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Calliditas Therapeutics US INC. | $211.93 | 2022-2025 | Tarpeyo |
| Astrazeneca Pharmaceuticals LP | $196.51 | 2019-2025 | Farxiga, Evusheld |
| Novartis Pharmaceuticals Corporation | $157.56 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $137.44 | 2021-2022 | |
| Cmp Pharma, INC. | $119.54 | 2020-2023 | Liqrev, Norliqva, Tadliq |
| Opko Pharmaceuticals, LLC | $111.60 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $106.74 | 2023-2025 | Austedo Xr, Austedo Xr |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $90.36 | 2019-2022 | |
| Novo Nordisk INC | $83.56 | 2021-2025 | Rybelsus, Ozempic |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Austin Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.